However, no significant differences seen in changes in glycated hemoglobin between long-term low-carb and control diets
FRIDAY, Aug. 2, 2024 (HealthDay News) — For individuals with type 2 diabetes, long-term low-carbohydrate diets (LCD) are efficacious for treatment of dyslipidemia but do not affect glycemic control, according to a review published online July 24 in the Journal of Diabetes Investigation.
Takahiro Ichikawa, from the Kyoto Prefectural University of Medicine in Japan, and colleagues conducted a systematic review to examine the association between long-term LCD and glycemic control in individuals with type 2 diabetes. Six studies met the inclusion criteria.
The researchers found no significant differences in changes in glycated hemoglobin (HbA1c) between long-term LCD and control diets. Furthermore, between long-term and control diets, there were no significant differences in the changes in weight loss, blood pressure, and low-density lipoprotein cholesterol. Compared with control diets, long-term LCD were associated with greater elevation in high-density lipoprotein cholesterol (standardized mean difference, 0.22) and a decrease in triglyceride levels (standardized mean difference, −0.19).
“Long-term LCD might be an important approach in the management of diabetic dyslipidemia in individuals with type 2 diabetes,” the authors write. “However, in the present study, long-term LCD were not found to be more effective than control diets in the reduction of HbA1c levels.”
Several authors disclosed ties to the pharmaceutical industry.
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis